Trial · NCT06654336
Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)
NCT06654336, Phase 2, Recruiting, Ontario Clinical Oncology Group (OCOG)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC). Trials, record NCT06654336. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06654336
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)
- NCT number
- NCT06654336
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 162 participants, estimated
- Lead sponsor
- Ontario Clinical Oncology Group (OCOG)
- Conditions
- Prostate Adenocarcinoma, Castration Sensitive Prostate Cancer
- Interventions
- Recurrence-directed therapy (RDT), ELIGARD 22.5mg
- First posted
- 2024-10-23
- Last updated
- 2026-10-13
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Composite progression free survival | Time from randomization to the occurrence of composite PFS event occurring up to the 36 month follow-up. | Biochemical, radiological or clinical progression \[composite PFS (cPFS) event\] |
| Secondary | Disease progression | Time from date of randomization, until the date of progression or death occurring up to the 36 month follow-up. | Disease progression: time to biochemical progression (bPFS) (proportion of bPFS events); Disease progression: proportion of conventional-imaging based progression (rPFS) (proportion of rPFS events); Disease progression: proportion with eugonadal progression (egPFS) |
| Secondary | Time to initiation of tertiary therapy; | Time of initial therapy to 36 month follow-up. | Any non-protocol treatment given for prostate cancer after protocol-specified intervention. |
| Secondary | Proportion of patients that develop castrate-resistant prostate cancer (CRPC) | During the 36 month follow-up. | Proportion of patients that develop castrate-resistant prostate cancer (CRPC) |
| Secondary | Overall survival. | During the 36 month follow-up. | Overall survival. |
| Secondary | Rate of early and late Grade 3 or higher GU and GI toxicity. | At 3, 6, 15 and 36 months. | The rate of early and late Grade 3 or higher GU and GI toxicity will be assessed at baseline, 3, 6, 15 and 36 months. The CTCAEv.5.0 (\> Grade 3, GI and GU) toxicity rates will be reported. |
| Secondary | Quality of life assessed by EORTC QLQ C30 | Completed by the study participant at scheduled follow-up visits (Months 3, 6, 15 and 36). | Study participant reported quality of life utilizing the following measurement EORTC QLQ C30 |
| Secondary | Quality of life assessed by EORTC QLQ PR25 questionnaire | Completed by the study participant at scheduled follow-up visits (Months 3, 6, 15 and 36). | |
| Secondary | Quality of life assessed by EORTC QLQ PRT20 questionnaire | Completed by the study participant at scheduled follow-up visits (Months 3, 6, 15 and 36). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06654336
GET https://conductscience.org/api/trials/v1/NCT06654336/registered